In addition, PD-1 blockade has a significantly lower rate of high-grade toxicities than other immunotherapies or standard therapies, because the anti-tumor immunity preferentially recognizes tumor-derived antigens, not self-antigens. The gene discussed is PDCD1; the disease is neoplasm.